Bone
metastases occur in approximately 70% of metastatic
breast cancer patients, often leading to skeletal
injuries. Current treatments are mainly palliative and underscore the unmet clinical need for improved
therapies. In this study, we provide preclinical evidence for an antimetastatic
therapy based on targeting
integrin β3 (β3), which is selectively induced on
breast cancer cells in bone by the local bone microenvironment. In a preclinical model of
breast cancer, β3 was strongly expressed on bone metastatic
cancer cells, but not primary mammary
tumors or visceral
metastases. In
tumor tissue from
breast cancer patients, β3 was significantly elevated on bone
metastases relative to primary
tumors from the same patient (n = 42). Mechanistic investigations revealed that TGFβ signaling through SMAD2/SMAD3 was necessary for
breast cancer induction of β3 within the bone. Using a
micelle-based nanoparticle
therapy that recognizes
integrin αvβ3 (αvβ3-MPs of ∼12.5 nm), we demonstrated specific localization to
breast cancer bone
metastases in mice. Using this system for targeted delivery of the chemotherapeutic
docetaxel, we showed that bone
tumor burden could be reduced significantly with less bone destruction and less hepatotoxicity compared with equimolar doses of free
docetaxel. Furthermore, mice treated with αvβ3-MP-docetaxel exhibited a significant decrease in bone-residing
tumor cell proliferation compared with free
docetaxel. Taken together, our results offer preclinical proof of concept for a method to enhance delivery of chemotherapeutics to
breast cancer cells within the bone by exploiting their selective expression of
integrin αvβ3 at that metastatic site.
Cancer Res; 77(22); 6299-312. ©2017 AACR.